NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/12/2026
Back to search
Official data from USPTO
MEDIVERA COMPOUNDING PHARMACY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
05/12/2026
Trademark type
Combined
Nice classes
35
Filing date
03/13/2025
Registration date
05/12/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/12/2026
Last transaction
05/12/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
07/01/2024
First use in commerce
07/01/2024
Drawing code
5
Owner type
03
Owner location
Troy, MI, US
Examiner
ORSCHELN, COLLEEN J
Law office
O50
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the words "MEDIVERA COMPOUNDING PHARMACY" with the word "MEDIVERA" stacked above the words "COMPOUNDING PHARMACY".
Holders and representatives
Holders
Diversified Pharmacy, Inc.
Representatives
Matthew J. Stark Price Heneveld LLP
Technical classification
Nice Classes
Class 35
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Retail compounding pharmacy services; Mail order compounding pharmacy services; Compounding pharmaceutical servicesprocessing online and telephone prescription orders in retail and central fill pharmacies
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/12/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/24/2026
PUBO
PUBLISHED FOR OPPOSITION
03/24/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/18/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/01/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/27/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/27/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/27/2026
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
12/08/2025
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
12/08/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/08/2025
GNRT
NON-FINAL ACTION E-MAILED
09/08/2025
CNRT
NON-FINAL ACTION WRITTEN
09/08/2025
DOCK
ASSIGNED TO EXAMINER
08/13/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/13/2025
MAFR
APPLICATION FILING RECEIPT MAILED
03/13/2025
NWAP
NEW APPLICATION ENTERED
03/13/2025
Continuous trademark protection
Get notified about every new filing that threatens MEDIVERA COMPOUNDING PHARMACY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.